677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancer
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797630789641306112 |
|---|---|
| author | Tc Wu Francis Worden Michael K Gibson Panayiotis Savvides Ellen Heimann-Nichols Richard Roden Yung-Nien Chang |
| author_facet | Tc Wu Francis Worden Michael K Gibson Panayiotis Savvides Ellen Heimann-Nichols Richard Roden Yung-Nien Chang |
| author_sort | Tc Wu |
| collection | DOAJ |
| first_indexed | 2024-03-11T11:12:08Z |
| format | Article |
| id | doaj.art-0dbd31056a8e4653a3dd39b4d027c2d8 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T11:12:08Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-0dbd31056a8e4653a3dd39b4d027c2d82023-11-11T12:10:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0677677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancerTc Wu0Francis Worden1Michael K Gibson2Panayiotis Savvides3Ellen Heimann-Nichols4Richard Roden5Yung-Nien Chang6Aff4 grid.21107.350000000121719311Obstetrics and GynecologyJohns Hopkins Medical Institutions Baltimore MD USA12University of Michigan Health System Comprehensive, Ann Arbor, MI, USA6Vanderbilt University Medical Center, Nashville, TN, USA2Mayo Clinic, Scottsdale, AZ, USA1Vanderbilt University Medical Center, Nashville, TN, USA4Johns Hopkins University, Baltimore, MD, USA5PapiVax Biotech, Inc., Taipei, Taipei, Taiwan |
| spellingShingle | Tc Wu Francis Worden Michael K Gibson Panayiotis Savvides Ellen Heimann-Nichols Richard Roden Yung-Nien Chang 677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancer Journal for ImmunoTherapy of Cancer |
| title | 677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancer |
| title_full | 677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancer |
| title_fullStr | 677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancer |
| title_full_unstemmed | 677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancer |
| title_short | 677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancer |
| title_sort | 677 phase ii trial assessing safety efficacy and immune correlates of heterologous prime boost with pbi 11 im and ta hpv im plus pembrolizumab for advanced pd l1 cps≥1 hrhpv oropharyngeal cancer |
| work_keys_str_mv | AT tcwu 677phaseiitrialassessingsafetyefficacyandimmunecorrelatesofheterologousprimeboostwithpbi11imandtahpvimpluspembrolizumabforadvancedpdl1cps1hrhpvoropharyngealcancer AT francisworden 677phaseiitrialassessingsafetyefficacyandimmunecorrelatesofheterologousprimeboostwithpbi11imandtahpvimpluspembrolizumabforadvancedpdl1cps1hrhpvoropharyngealcancer AT michaelkgibson 677phaseiitrialassessingsafetyefficacyandimmunecorrelatesofheterologousprimeboostwithpbi11imandtahpvimpluspembrolizumabforadvancedpdl1cps1hrhpvoropharyngealcancer AT panayiotissavvides 677phaseiitrialassessingsafetyefficacyandimmunecorrelatesofheterologousprimeboostwithpbi11imandtahpvimpluspembrolizumabforadvancedpdl1cps1hrhpvoropharyngealcancer AT ellenheimannnichols 677phaseiitrialassessingsafetyefficacyandimmunecorrelatesofheterologousprimeboostwithpbi11imandtahpvimpluspembrolizumabforadvancedpdl1cps1hrhpvoropharyngealcancer AT richardroden 677phaseiitrialassessingsafetyefficacyandimmunecorrelatesofheterologousprimeboostwithpbi11imandtahpvimpluspembrolizumabforadvancedpdl1cps1hrhpvoropharyngealcancer AT yungnienchang 677phaseiitrialassessingsafetyefficacyandimmunecorrelatesofheterologousprimeboostwithpbi11imandtahpvimpluspembrolizumabforadvancedpdl1cps1hrhpvoropharyngealcancer |